Is Adlai Nortye Ltd. (ANL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.3% / 30% | 18.5% / 30% | 0.4% / 30% | N/A | ✓ HALAL |
| DJIM | 8.3% / 33% | 18.5% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| MSCI | 38.2% / 33% | 85.5% / 33% | 1.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 8.3% / 33% | 18.5% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| FTSE | 38.2% / 33% | 85.5% / 33% | 1.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -139.0% | |
| Return on Assets (ROA) | -29.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$52M |
| Free Cash Flow | -$52M |
| Total Debt | $27M |
| Debt-to-Equity | 562.6 |
| Current Ratio | 1.0 |
| Total Assets | $71M |
Price & Trading
| Last Close | $6.75 |
| 50-Day MA | $7.61 |
| 200-Day MA | $3.08 |
| Avg Volume | 991K |
| Beta | -1.5 |
|
52-Week Range
$0.88
| |
About Adlai Nortye Ltd. (ANL)
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Adlai Nortye Ltd. (ANL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Adlai Nortye Ltd. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Adlai Nortye Ltd.'s debt ratio?
Adlai Nortye Ltd.'s debt ratio is 8.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 38.2%.
What are Adlai Nortye Ltd.'s key financial metrics?
Adlai Nortye Ltd. has a market capitalization of $379M. Return on equity stands at -139.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.